We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

11 hedge funds and large institutions have $1.78M invested in Moleculin Biotech in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more capital inflows, than outflows

Capital inflows: $1.13M | Capital outflows: $227K

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

10% more funds holding

Funds holding: 10 → 11 (+1)

1.96% more ownership

Funds ownership: 5.58% → 7.54% (+2%)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CVI Holdings
CVI Holdings
Delaware
+$477K
2
Armistice Capital
Armistice Capital
New York
+$298K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$179K
4
Renaissance Technologies
Renaissance Technologies
New York
+$119K
5
Truist Financial
Truist Financial
North Carolina
+$59.6K

Top Sellers

Rank Fund Capital Flow
1
CIBC World Market
CIBC World Market
Ontario, Canada
-$170K
2
Citadel Advisors
Citadel Advisors
Florida
-$22K
3
Two Sigma Securities
Two Sigma Securities
New York
-$21K
4
Virtu Financial
Virtu Financial
New York
-$13K
5
UBS Group
UBS Group
Switzerland
-$1K

MBRX Hedge Fund Activity: Q1 2019 in Review

11 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2019, worth a combined $1.78M — up 13% from $1.58M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new MBRX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was CVI Holdings, opening a new position worth an estimated $477K. The largest seller was CIBC World Market, exiting entirely with an estimated $170K sold.

  • 11 institutional investors held Moleculin Biotech (MBRX) as of Q1 2019, up from 10 in Q4 2018.
  • Funds reported $1.78M of Moleculin Biotech stock for Q1 2019, up 13% quarter-over-quarter.
  • 2 funds opened new Moleculin Biotech positions in Q1 2019 and 1 closed out, a net change of +1 holder.
  • The largest Moleculin Biotech buyer in Q1 2019 was CVI Holdings, an estimated $477K added.
  • The largest Moleculin Biotech seller in Q1 2019 was CIBC World Market, an estimated $170K sold.

Based on aggregated 13F filings for Q1 2019.